ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL).

被引：0
|
作者：
Flinn, Ian W.
Jacobson, Caron Alyce
Nastoupil, Loretta J.
Morschhauser, Franck
Davies, Andrew
Buske, Christian
Corradini, Paolo
Guillermo, Armando Lopez
Reshef, Ran
Parameswaran, Vinod
Sehgal, Alison
Tees, Michael Timothy
Lui, Christine
Xue, Wei
Beygi, Sara
Grechko, Nikolay
Bolsue, Pisita
Giovanetti, Alessandro
To, Christina Ann
Nahas, Myrna
机构：
[1] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[2] Dana Farber Canc Inst, Boston, MA USA
[3] MD Anderson Canc Ctr, Houston, TX USA
[4] Univ Lille, Ctr Hosp Univ, Lille, France
[5] Univ Southampton, Southampton Expt Canc Med Ctr, Southampton, Hants, England
[6] Univ Hosp Ulm, Comprehens Canc Ctr Ulm, Inst Expt Canc Res, Ulm, Germany
[7] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[8] Univ Barcelona, Barcelona, Spain
[9] Columbia Univ, Med Ctr, New York, NY USA
[10] Avera Med Grp Hematol Transplant & Cellular Thera, Sioux Falls, SD USA
[11] Univ Pittsburgh, Med Ctr, Hillman Canc Ctr, Pittsburgh, PA USA
[12] Colorado Blood Canc Inst, Denver, CO USA
[13] Kite, Santa Monica, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7579
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.
    Locke, Frederick Lundry
    Ghobadi, Armin
    Lekakis, Lazaros J.
    Miklos, David Bernard
    Jacobson, Caron A.
    Jacobsen, Eric D.
    Braunschweig, Ira
    Oluwole, Olalekan O.
    Siddiqi, Tanya
    Lin, Yi
    Reagan, Patrick Michael
    Farooq, Umar
    Deol, Abhinav
    Bot, Adrian
    Rossi, John M.
    Jiang, Yizhou
    Xue, Allen
    Go, William Y.
    Neelapu, Sattva Swarup
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.
    Locke, Frederick Lundry
    Ghobadi, Armin
    Jacobson, Caron A.
    Jacobsen, Eric D.
    Miklos, David Bernard
    Lekakis, Lazaros J.
    Braunschweig, Ira
    Oluwole, Olalekan O.
    Lin, Yi
    Siddiqi, Tanya
    Deol, Abhinav
    Reagan, Patrick Michael
    Farooq, Umar
    Bot, Adrian
    Jiang, Yizhou
    Rossi, John M.
    Xue, Allen
    Go, William Y.
    Neelapu, Sattva Swarup
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] Outcomes of Patients Aged 65 Years in ZUMA-1, a Pivotal Phase 1/2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Refractory Large B Cell Lymphoma
    Neelapu, Sattva S.
    Jacobson, Caron A.
    Oluwole, Olalekan O.
    Munoz, Javier
    Deol, Abhinav
    Miklos, David B.
    Bartlett, Nancy L.
    Braunschweig, Ira
    Jiang, Yizhou
    Kim, Jenny J.
    Zheng, Lianging
    Rossi, John M.
    Locke, Frederick L.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S19 - S20
  • [44] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes
    Khurana, Arushi
    Bailey, Megumi
    Iqbal, Madiha
    Bansal, Radhika
    Lee, Catherine J.
    Hunter, Bradley
    Lunning, Matthew A.
    Jaglowski, Samantha
    Jain, Michael D.
    Dahiya, Saurabh
    Bachanova, Veronika
    Farooq, Umar
    Ahmed, Sairah
    Hill, Brian T.
    Munoz, Javier L.
    Patel, Krish
    Oluwole, Olalekan O.
    Lin, Yi
    BLOOD, 2022, 140 : 4657 - 4660
  • [45] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
    Oluwole, Olalekan O.
    Forcade, Edouard
    Munoz, Javier
    de Guibert, Sophie
    Vose, Julie M.
    Bartlett, Nancy L.
    Lin, Yi
    Deol, Abhinav
    McSweeney, Peter A.
    Goy, Andre H.
    Kersten, Marie Jose
    Jacobson, Caron A.
    Farooq, Umar
    Minnema, Monique C.
    Thieblemont, Catherine
    Timmerman, John
    Stiff, Patrick
    Avivi, Irit
    Tzachanis, Dimitrios
    Zheng, Yan
    Vardhanabhuti, Saran
    Nater, Jenny
    Shen, Rhine R.
    Miao, Harry
    Kim, Jenny
    van Meerten, Tom
    BLOOD, 2022, 140 : 10399 - 10401
  • [46] Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): Outcomes of the phase 2 ZUMA-14 study.
    Strati, Paolo
    Leslie, Lori Ann
    Shiraz, Parveen
    Budde, L. Elizabeth
    Oluwole, Olalekan O.
    Ulrickson, Matthew
    Ramakrishnan, Aravind
    Sun, Jennifer
    Shen, Rhine
    Kanska, Justyna
    McCroskery, Peter
    Dong, Jinghui
    Schupp, Marco Andreas
    Xu, Hairong
    Patel, Krish
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] PRELIMINARY RESULTS OF THE EARLY USE OF CORTICOSTEROIDS WITH AXICABTAGEN CILOLEUCEL (AXI-CEL) IN PATIENTS DIAGNOSED WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (R/R LBCL)
    Max, Topp S.
    Van Meerten, T.
    Wermke, M.
    Pieternella, Lugtenburg J.
    Monique, Minnema C.
    Kevin, Song W.
    Thieblemont, C.
    Jiang, Y.
    Plaks, V
    Kerber, A.
    Kersten, M. J.
    HAEMATOLOGICA, 2019, 104 : 98 - 98
  • [48] Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product
    Jacobson, Caron A.
    Locke, Frederick L.
    Miklos, David B.
    Vose, Julie M.
    Lin, Yi
    Budde, Lihua E.
    Maloney, David G.
    Jaglowski, Samantha
    Riedell, Peter A.
    Lekakis, Lazaros J.
    Perales, Miguel-Angel
    Kim, Jenny J.
    Kawashima, Jun
    Yang, Yin
    Rossi, John M.
    Goyal, Lovely
    Neelapu, Sattva S.
    BLOOD, 2020, 136
  • [49] End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma
    Jacobson, Caron A.
    Locke, Frederick L.
    Miklos, David B.
    Herrera, Alex F.
    Westin, Jason R.
    Lee, Jennifer
    Rossi, John M.
    Zheng, Lianqing
    Avanzi, Mauro P.
    Roberts, Zachary J.
    Sun, Jennifer
    BLOOD, 2018, 132
  • [50] End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma
    Jacobson, Caron A.
    Locke, Frederick L.
    Miklos, David B.
    Herrera, Alex F.
    Westin, Jason R.
    Lee, Jennifer
    Rossi, John M.
    Sun, Jennifer
    Zheng, Lianqing
    Avanzi, Mauro P.
    Roberts, Zachary J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
12345